Update in Primary Care, Feb 2019- Part 2

Here’s the second half of the Update in Primary Care, presented with Peter Phan at the Southern SGIM meeting in Houston, TX.

I summarized some of this evidence in a recent post on diabetes drugs- check this if you (like me) can’t keep the acronyms straight. This paper was published in JAMA in April.

This was a network meta-analysis designed to compare outcomes of SGLT-2 Inhibitors, GLP-1 Agonists, and DPP-IV Inhibitors. There were A LOT of results here, but the main takaway for me is that SGLT-2 inhibitors and GLP-1 receptor agonists have a mortality benefit in diabetics. The reduced mortality is more pronounced in SGLT-2 Inhibitors, and this class also showed significant reduction of heart failure events.

This video from JAMA provides a great overview of the study.

Switching gears, this paper compared vaginal estradiol and a fancy vaginal gel with placebo estradiol and placebo gel for patients with vulvovaginal atrophy symptoms. All patients got a vaginal tablet and a gel- either active tablet/placebo gel, active gel/placebo tablet, or dual placebo.

Women reported significant symptoms at baseline- including 50% reporting that they frequently felt distressed with sexual functioning.

Most women had improved symptoms, no matter the treatment. But it didn’t matter which treatment they got, so a cheaper OTC lubricant seems just as good as an expensive prescription for topical estradiol.

Finally, a paper about primary care workflow. There is a lot of burnout in medicine, and in primary care. One reason is the clerical burden that doctors have- entering orders, signing forms, and writing notes for billing purposes. Scribes have been proposed as a potential answer to this clerical overload.

This study gave scribes to 18 primary care physicians (IM and Family Med) in the Kaiser Permanente system. All the practices had 3 month alternating blocks of time with a scribe, and time without a scribe. They measured MD satisfaction, patient satisfaction, perceived time working in the EMR outside of work hours, and actual time in the EMR.

During their time with the scribe, MDs were much more likely to report spending <1 hour per day and <1 hour per weekend working in the electronic medical record. Patients felt that doctors were spending more time interacting with them rather than the computer. Objectively, MDs were more likely to get phone and clinic encounters done on time (perhaps important to your C-suite) and spent 77 minutes less time per half day of clinic in documentation. They actually only spent 17 minutes fewer per week logged into the EMR during off hours.

Take homes for Part 2

  • Think about SGLT-2 inhibitors and GLP-1 Inhibitors for your diabetic patients. They seem to have a mortality and cardiovascular benefit over other agents
  • Try OTC topical lubricants first for vulvovaginal atrophy symptoms.
  • Think about scribes in your primary care practice if you are feeling overwhelmed by clerical work.
Advertisement

Diabetes Treatment Guidelines 2019

Long time coming…

but I’m back. Will try using this site as place to collect clinical pearls and educational resources from around the internets. Up first- Diabetes.

There are many new treatments for DM, and I can’t keep the initials straight, so first up, my round-up of DM treatments.

Metformin- first line therapy along with lifestyle modification.

GLP-1 RA: end in “glutide”. These are all injectable, some now once weekly. Some have proven CVD reduction benefits. In order of CVD benefit: Liraglutide (Victoza/Saxenda), Semaglutide (Ozempic), Exanatide (Byetta/Byderon).

SGLT2i: end in “gliflozin” These also have been shown to reduce CVD events, along with heart failure and progression of CKD. Empagliflozin (Jardiance) and Canagliflozin (Invokana) are examples.

DPP-4i: “Gliptins” Work by increasing Incretin, which helps the body make insulin when needed, and decreases glucose creation in the liver. Sitagliptin (Januvia) and Saxagliptin (Onglyza) are examples.

These are the most updated Standards of Care in DM, published Jan 2019. Here are the AACE executive summary and slide decks. 

I am teaching about treatment of DM, so here are some of the most relevant figures. Smart people have also told me that there is a great app with these algorithms. Search AACE Type 2 Diabetes.

First and Second line Treatments

Adding Injectable Medicines

And because conflict is interesting, here are the ACP guidelines for DM published last year, which set off a bit of a firestorm between Internists and Endocrinologists. The main differences have to do with treatment targets. ACP recommends aiming for HbA1c between 7-8% for most patients, and even higher for patients with less than 10 years life expectancy, nursing home patients, or with other chronic diseases. They feel we should focus on limiting harms and avoiding hypoglycemia in this population.   The ADA suggests keeping HbA1c less than 7% for most patients, with tighter targets for healthier patients who are doing well with current treatment, or those with cardiovascular disease. They are OK with higher HbA1c targets (<8%) in those who have demonstrated hypoglycemia, limited life expectancy, or comorbidities.

Enjoy!!

Managing Sexual Assualt in Primary Care

Thanks to those who participated in a great discussion in AMR last week. I wanted to share some of what we talked about here…

Sexual assault is an unusal complaint inside of a primary care clinic.  Many victims head straight for the ER or a Rape Crisis Center, others never report their attack. But for many, their primary care doctor may seem like a trusted source for health care in a very scary and chaotic situation. Since it is also a scary and chaotic situation for the provider, I thought that an organized process may help you know what to do in such a scenario.


Legal Issues

The patient may need or want an exam in order to collect evidence for future charges against an attacker. There is a very specialized process that is used to collect evidence, and maintain the chain of custody.  I would recommend that you contact your Emergency Dept or Rape Crisis Center for help.  In Birmingham, the Crisis Center offers Sexual Assault Nurse Examiner (SANE) Exams in a safe and secure facility, and may be a more comfortable alternative to an ED.  They have a SANE nurse on call 24/7. Many times, this exam must be done within 72 hours of the attack.

Pregnancy Prevention

Most women should be offered post-coital contraception after a sexual assault.  The most effective oral option is Le
vonorgestrel, (Plan B is one brand name).  Ulipristal (Ella) is a newer form of emergency contraception that is effective up to 120 hours after unprotected sex.

 

STI Prevention

The CDC recommends antibiotic prophylaxis for GC, Chlamydia, and Trichomonas.  If your patient declines, you should see her back in a week for testing.  You need to give (all single dose therapies):

  • Ceftriaxone 250mg IM for Gonorrhea
  • Azithromycin 1g PO for Chlamydia
  • Metronidazole 2g PO for Trichomonas

Hepatitis B Prevention

If the Hepatitis B status of the attacker is not known, and the victim is not already immune, the victim should receive the Hepatitis B vaccine on first visit, and then at 1 and 6 months.  If the attacker has Hepatitis B, then you should offer HBIG.

HIV Prevention

There is some data that post-exposure prophylaxis with antiretroviral drugs prevents HIV transmission. Most of this data is in the healthcare setting, when folks like us are exposed with needles. The studies done in sexual exposure and IV drug users are all small and observational. Side effects with these medicines are fairly common, and usually of the GI variety.

Given limited data, and relatively low risk of transmission for a single sexual exposure (0.1% for consensual vaginal intercourse and 2% for consensual anal intercourse- transmission rates with nonconsensual sex are likely to be higher), the CDC only recommends post exposure prophylaxis (PEP) if:

  • The assailant is known to be HIV positive
  • The victim presents within 72 hours
  • There was exposure OF: eye, mouth, vaginal, rectum, other mucus membrane or nonintact skin
  • WITH: semen, vaginal fluid, blood, rectal secretions, milk, or other bodily fluids that are known to transmit HIV.

However, they do give you an option to treat other patients on a case-by-case basis. Many experts recommend that PEP is offered to all victims of sexual assault that present in the first 72 hours and have a chance at HIV exposure.  If you were going to prescribe, it should start within 72 hours (the earlier the better), and continue for 4 weeks. Three drug combinations are usually used, the same as in occupational HIV PEP.

  • Tenofovir/emtricitabine 300/200 plus Dolutegravir 50mg once daily
  • Tenofovir/emtricitabine 300/200 plus Raltegravir 400mg twice daily

Psychologic Support

Probably the most important thing that you can do. Your patient came to use because you were trusted, available, and supportive. You need to continue to be those things. After an assault, many victims will struggle with nightmares, anorexia, guilt, anxiety, and PTSD.  As a primary care doctor, you can gently ask about these issues, and guide your patients to helpful therapies and supportive environments. Again, rely on your local resources for crisis counseling and psychiatry, in addition to using all of your own talents.

Here is a NEJM article (subscription needed) if you are interested in reading more: NEngl J Med 2011; 365:834-841.